Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations

Pharmacogenetics

Volumn 7, Issue 1, 1997, Pages 59-64

  Goldstein, Joyce A ^a   Ishizaki, Takashi ^b   Chiba, Kan ^b   De Morais, Sonia M F ^a   Bell, Douglas ^a   Krahn, Peter M ^c   Price Evans, David A ^d  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d Riyadh Armed Forces Hospital ^*  (Saudi Arabia)

Author keywords

CYP2C19; mephenytoin polymorphism

Indexed keywords

MEPHENYTOIN;

ALLELE; ARTICLE; CAUCASIAN; DRUG METABOLISM; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPAN; MUTATION; NORMAL HUMAN; PHENOTYPE; POPULATION; PRIORITY JOURNAL; SAUDI ARABIA; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ARABS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CONFIDENCE INTERVALS; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; PHILIPPINES; POLYMORPHISM, GENETIC; SAUDI ARABIA; TAIWAN;

EID: 0030904031     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199702000-00008     Document Type: Article

References (33)

1. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
2. Balian JD, Sukhova N, Harris JW, Hewett J, Pickel L, Goldstein JA, Woosley RL, Flockhart DA. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 1995: 57, 662-669.
3. Baumann PM, Jonzier-Perez L, Kerb A, Küpfer D, Tingueley D, Schöpf J. Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986: 1, 102-112.
4. Bertilsson L, Lou Y-Q, Du YL, Liu Y, Kuang X-Y, Liao X-M, Wang K-Y, Reviriego J, Iselius L, Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992: 51, 388-397.
5. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995: 29, 192-209.
6. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995: 5, 312-317.
7. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evens WE, Gonzalaz FJ, Huang JD, Idle JR, Ingelman-Sunberg M, Ishizaki T, Jacqz-Aigain E, Meyer UA, Neber DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
8. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994a: 269, 15419-15422.
9. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b: 46, 594-598.
10. de Morais SMF, Goldstein JA, Xie H-G, Huang S-L, Lu YP, Xia H, Xiao Z-S, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995: 58, 404-412.
11. Edieke TI, Goldstein JA, de Morais SMF, Hajiloo L, Butler M, Chapdelaine P, Wilkinson GR. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996: 6, 357-360.
12. Evans DAP, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995: 5, 64-71.
13. Fleiss JL. Statistical methods for rates and proportions, 2nd edition, New York: John Wiley and Sons. Inc., 1981.
14. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994: 33, 1743-1752.
15. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, Liao C-L, Zhang L-M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989: 46, 198-207.
16. Islam SI, Idle JR, Smith RL. The polymorphic 4-hydroxylation of debrisoquine in a Saudi Arab population. Xenobiotica 1980: 11, 819-825.
17. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985: 19, 483-487.
18. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984: 26, 753-759.
19. Lou Y-C, Ying L, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987: ii, 852-853.
20. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38, 402-408.
21. Nei M, Saitou N. Genetic relationship of human population and ethnic differences in reactions to drugs and food. In: Kalow W, Goedde HW, Agarwald DP, eds. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R. Uss. 1986: 21-37.
22. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omicinski CJ, Johnson EF. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichi coli. Arch of Biochem and Biophys 1995: 323, 87-96.
23. Reed TE. Caucasian genes in the American Negro. Science 1969: 165, 762-768.
24. Romkes M, Faletto MB, Blaisdell SA, Raucy JL, Goldstein JA. Cloning and expression of complementary cDNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991: 30, 3247-3255.
25. Sohn D-R, Kusaka M, Ishizaki T, Shin S-F, Vang I-J, Shin JF. Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992: 52, 160-169.
26. Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans. European-Americans and Taiwanese. Pharmacogenetics 1994: 4, 185-192.
27. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug polymorphism. Clin Pharmacol Ther 1984a: 36, 773-80.
28. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr Biomed Appli 1984b: 307, 121-127.
29. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987: 15, 277-279.
30. Weir BS. Genetic data analysis. Sunderland. MA: Sinauer Associates, Int., 1990: 35, 74.
31. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989: 43, 53-76.
32. Wrighton SA, Stevens JC, Becker BW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993: 306, 240-245.
33. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of urinary S-/R- mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991: 31, 350-352.